

## Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has confirmed that the shortage for Deferoxamine Mesylate 500 mg/vial Injection (DIN 02241600) manufactured by Pfizer Canada ULC has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **April 28, 2025**. The following grouping was removed from the Critical Supply Product List **March 27, 2025**.

### DEFEROXAMINE MESYLATE

#### 500 MG / VIAL INJECTION

00002241600	DEFEROXAMINE MESYLATE	PFI	\$ 15.1690
00001981242	DESFERAL	NOV	\$ 17.1780

Alberta Blue Cross has confirmed that the shortage for Clarus 40 mg Capsule (DIN 02257963) manufactured by Viatris Canada has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **May 5, 2025**. The following grouping was removed from the Critical Supply Product List **April 4, 2025**.

### ISOTRETINOIN

#### 40 MG CAPSULE

00002257963	CLARUS	MYP	\$ 1.9003
00000582352	ACCUTANE	HLR	\$ 1.9948

Alberta Blue Cross has confirmed that the shortage for Taro-Budesonide 0.25 mg/ml Inhalation Suspension (DIN 02494272) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **May 7, 2025**. The following grouping was removed from the Critical Supply Product List **April 7, 2025**.

### BUDESONIDE

#### 0.25 MG / ML INHALATION SUSPENSION

00002494272	TARO-BUDESONIDE	TAR	\$ 0.3593
00001978918	PULMICORT NEBUAMP	AZC	\$ 0.5306

*continued next page*

continued from previous page

Alberta Blue Cross has confirmed that the shortage for Sandoz Carbamazepine CR 200 mg Sustained-Release Tablet (DIN 02261839) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **May 12, 2025**. The following grouping was removed from the Critical Supply Product List **April 15, 2025**.

## CARBAMAZEPINE

### 200 MG SUSTAINED-RELEASE TABLET

00002261839	SANDOZ CARBAMAZEPINE CR	SDZ	\$ 0.3845
00000773611	TEGRETOL CR	NOV	\$ 0.4785

Alberta Blue Cross has confirmed that the shortage for Sandoz Carbamazepine CR 400 mg Sustained-Release Tablet (DIN 02261847) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA Price Policy will be reapplied to the following grouping effective **May 15, 2025**. The following grouping was removed from the Critical Supply Product List **April 15, 2025**.

## CARBAMAZEPINE

### 400 MG SUSTAINED-RELEASE TABLET

00002261847	SANDOZ CARBAMAZEPINE	SDZ	\$ 0.7689
00000755583	TEGRETOL CR	NOV	\$ 0.9573

## Removal of Temporary Benefits from ADBL

Due to the unavailability of Sandoz Carbamazepine CR 200 mg Sustained-Release Tablet (DIN 02261839), Sandoz Carbamazepine CR 400 mg Sustained-Release Tablet (DIN 02261847), Tegretol CR 200 mg Sustained-Release Tablet (DIN 00773611) and Tegretol CR 400 mg Sustained-Release Tablet (DIN 00755583) manufactured by Novartis Pharmaceuticals Canada Inc., **Carbamazepine 200 mg Extended-Release Tablet (US) (PIN 09858341) and Carbamazepine 400 mg Extended-Release Tablet (US) (PIN 09858342)** manufactured by Septa Pharmaceuticals Inc., were added as a temporary benefits for the *Alberta Drug Benefit List (ADBL)*.

Alberta Blue Cross has confirmed that the shortage for Sandoz Carbamazepine CR 200 mg Sustained-Release Tablet (DIN 02261839), Sandoz Carbamazepine CR 400 mg Sustained-Release Tablet (DIN 02261847), Tegretol CR 200 mg Sustained-Release Tablet (DIN 00773611) and Tegretol CR 400 mg Sustained-Release Tablet (DIN 00755583) has been resolved.

**Carbamazepine 200 mg Extended-Release Tablet (US) (PIN 09858341) and Carbamazepine 400 mg Extended-Release Tablet (US) (PIN 09858342)** will no longer be considered temporary benefits for the *ADBL* **after May 15, 2025**.

The above grouping was removed from the Critical Supply Product List **April 15, 2025**.

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)  
403-294-4041 (Calgary and area)  
1-800-361-9632 (toll free)  
FAX 780-498-8406 (Edmonton and area)  
FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct-bill drug claims.

Visit [ab.bluecross.ca/providers/pharmacy-home.php](http://ab.bluecross.ca/providers/pharmacy-home.php)

